Obesity Surgery

, Volume 22, Issue 6, pp 950–955 | Cite as

Obesity and Inflammation: Change in Adiponectin, C-Reactive Protein, Tumour Necrosis Factor-Alpha and Interleukin-6 After Bariatric Surgery

  • Fátima Illán-GómezEmail author
  • Manuel Gonzálvez-Ortega
  • Isabel Orea-Soler
  • Ma. Soledad Alcaraz-Tafalla
  • Aurora Aragón-Alonso
  • Mercedes Pascual-Díaz
  • Matías Pérez-Paredes
  • Ma. Luisa Lozano-Almela
Clinical Research



Obesity is associated with a low-grade inflammatory state. A causal association between inflammation and atherosclerosis has been suggested. The aim of this study was to evaluate changes in the proinflammatory profile of morbidly obese patients after weight loss following bariatric surgery.


In this study, we measured levels of adiponectin, high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) and their relation to insulin resistance and lipid parameters in 60 morbidly obese women at baseline and 3, 6 and 12 months after gastric bypass.


Twelve months after surgery, there was a significant increase in plasma levels of adiponectin (p < 0.001) and high-density lipoprotein cholesterol (p < 0.01) and a significant decrease in levels of IL-6 (p < 0.001), hs-CRP (p < 0.001), cholesterol (p < 0.001), triglycerides (p < 0.001), low-density lipoprotein cholesterol (p < 0.001), glucose (p < 0.001), insulin (p < 0.001) and homeostasis model assessment (HOMA; p < 0.001). At 12 months, correlations were seen between IL-6 levels and the following: body mass index (BMI) (r = 0.53, p < 0.001), insulin (r = 0.51, p < 0.001) and HOMA (r = 0.55, p < 0.001). Also, hs-CRP levels correlated with BMI (r = 0.40, p = 0. 004), triglycerides (r = 0.34, p = 0.017), insulin (r = 0.50, p = 0.001) and HOMA (r = 0.46, p = 0.002).


In patients with morbid obesity, significant weight loss is followed by a significant improvement in the inflammatory state, insulin sensitivity and lipid profile. A relationship exists between improved inflammatory profile and insulin sensitivity.


Obesity Bariatric surgery Adiponectin TNF-α IL-6 hs-CRP Inflammation Insulin resistance 


Conflict of interest

Fátima Illán Gómez, Manuel Gonzálvez Ortega, Isabel Orea Soler, Ma. Soledad Alcaraz Tafalla, Aurora Aragón Alonso, Mercedes Pascual Díaz, Matías Pérez Paredes, Ma. Luisa Lozano Almela declare that they have no conflicts of interest.

Supplementary material

11695_2012_643_MOESM1_ESM.pdf (511 kb)
ESM 1 (PDF 510 kb)


  1. 1.
    Wexler Dj, Hu FB, Manson JE. Mediating effects of inflammatory biomarkers on insulin resistance associated with obesity. Obes Res. 2005;13:1772–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–77.PubMedCrossRefGoogle Scholar
  4. 4.
    Guerre Millo M. Adipose tissue and adipokines for better or worse. Diabetes Metab. 2004;30:13–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Trayhum P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans. 2005;33:1078–81.CrossRefGoogle Scholar
  6. 6.
    Winkler G, Kiss S, Keszthelyi L. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2003;149:129–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Inmunol. 2006;6:772–83.CrossRefGoogle Scholar
  8. 8.
    Guerre Millo M. Adiponectin: an update. Diabetes Metab. 2008;34:12–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Hager GR, van Haeten TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29:2959–71.CrossRefGoogle Scholar
  10. 10.
    Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–3.PubMedGoogle Scholar
  13. 13.
    Ridker PM, Brown NJ, Vaughan DE. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25):IV6–19. Suppl 1.PubMedCrossRefGoogle Scholar
  14. 14.
    Brolin RE. Bariatric surgery and long-term control of morbid obesity. JAMA. 2002;288:2793–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Sjöström L, Lindroos A, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Scheen AJ, Letiexhe M, Rorive M, et al. Bariatric surgery: 10-year results of the Swedish Obese Subjects Study. Rev Méd Liège. 2005;60(2):121–5.PubMedGoogle Scholar
  17. 17.
    Sugerman HJ, Wolfe LG, Sica DA. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237(6):751–8.PubMedGoogle Scholar
  18. 18.
    Buchwald H. Bariatric surgery: a systematic review and metaanalysis. JAMA. 2004;292(14):1724–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Capella RF, Capella JF. Reducing early technical complications in gastric by-pass surgery. Obes Surg. 1997;7:149–57.PubMedCrossRefGoogle Scholar
  20. 20.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPEN. 2008;32:645–7.CrossRefGoogle Scholar
  22. 22.
    Vazquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Vilarrasa N, Vendrell J, Sanchez-Santost R. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol. 2007;67:679–86.CrossRefGoogle Scholar
  24. 24.
    Forsythe LK, Wallace JMW, Livingstone MBE. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21:117–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Butner KL, Nickols-Richardson SM, Clark SF, et al. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg. 2010;20:559–68.PubMedCrossRefGoogle Scholar
  26. 26.
    Garcia de la Torre N, Rubio MA, Bordiú E. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008;93:4276–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Trakhtenbroit MA, Leichman JG, Algahim MF, et al. Body weight, insulin resistance, and serum adipokine levels two years after two types of bariatric surgery. Am J Med. 2009;122:435–42.PubMedCrossRefGoogle Scholar
  28. 28.
    Swarbrick MM, Stanhope KL, Austrheim-Smith IT, et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia. 2008;51:1901–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Dandona P. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 1998;83(8):2907–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Cottam DR, Mattar SG, Barinas-Mitchell E, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg. 2004;14(5):589–600.PubMedCrossRefGoogle Scholar
  31. 31.
    Kopp H. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23(6):1042–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Vazquez LA, Pazos F, Berrezueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90(1):316–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Appachi S, Kelly KR, Schauer PR, et al. Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from “adiposopathy”. Obes Surg. 2011;21:1928–36.PubMedCrossRefGoogle Scholar
  34. 34.
    Whitson B, Leslie D, Kellogg T, et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res. 2007;142(2):295–300.PubMedCrossRefGoogle Scholar
  35. 35.
    Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.PubMedCrossRefGoogle Scholar
  36. 36.
    Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999;277:E971–5.PubMedGoogle Scholar
  37. 37.
    Hauner H, Bender M, Haastert B, et al. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord. 1998;22(12):1239–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Fernández-Real JM, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes. 1998;47:1752–62.CrossRefGoogle Scholar
  39. 39.
    Straczkowski M, Kowalska I, Stepien A. Increased plasma soluble tumor necrosis factor-2 receptor level in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes Cares. 2002;25(10):1824–8.CrossRefGoogle Scholar
  40. 40.
    Bluher M, Kratzsch J, Paschke R. Plasma levels of TNF-α, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care. 2001;24:328–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Zittermann A. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105–12.PubMedCrossRefGoogle Scholar
  42. 42.
    Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15(2):145–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Kim KY, Kim JK, Han SH, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol. 2006;176:5958–64.PubMedGoogle Scholar
  44. 44.
    Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Haque WA, Shimomura I, Matsuzawa Y, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002;87:2395.PubMedCrossRefGoogle Scholar
  46. 46.
    Weyer C, Funahashi T. Tanaka S et al Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Cowan GS, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998;22:987–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2012

Authors and Affiliations

  • Fátima Illán-Gómez
    • 1
    Email author
  • Manuel Gonzálvez-Ortega
    • 2
  • Isabel Orea-Soler
    • 1
  • Ma. Soledad Alcaraz-Tafalla
    • 1
  • Aurora Aragón-Alonso
    • 1
  • Mercedes Pascual-Díaz
    • 1
  • Matías Pérez-Paredes
    • 2
  • Ma. Luisa Lozano-Almela
    • 3
  1. 1.Department of Endocrinology and NutritionUniversity Hospital Morales MeseguerMurciaSpain
  2. 2.Department of CardiologyUniversity Hospital Morales MeseguerMurciaSpain
  3. 3.Department of HematologyUniversity Hospital Morales MeseguerMurciaSpain

Personalised recommendations